Recruiting

Testing a new skin cancer drug alone and with immunotherapy

Plain-English translation of NCT06624644 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new drug called to see if it can help treat advanced melanoma (a type of skin cancer) that has stopped responding to previous immune-based treatments. You would receive either the medication alone, the medication plus an existing immunotherapy drug called , or a doctor's choice of standard treatments. The researchers believe this new approach may work better for patients whose cancer has become resistant to earlier therapies.

Many melanoma patients eventually develop resistance to current immune checkpoint inhibitor therapies, meaning their cancers start growing again despite treatment. This trial is exploring whether this new medication could help patients at this critical point when their options are limited.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced melanoma that cannot be surgically removed
your cancer has progressed despite prior treatment with anti-PD-1 immunotherapy drugs
you have a specific genetic variation (called GPER C/C) that makes you eligible for this study
you are in good enough general health to tolerate the treatment (Eastern Cooperative Oncology Group performance status 0-1)
you can swallow tablets and are willing to receive the doctor's choice treatment if randomly assigned to that group

You likely don't qualify if…

you have certain rare subtypes of melanoma, including mucosal, ocular, or acral lentiginous types
you have received other cancer treatments or radiation within the past 2-4 weeks
you have had an organ or tissue transplant
you have an unstable autoimmune disease or serious immunodeficiency condition
you previously had a severe allergic reaction to pembrolizumab or similar anti-PD-1 drugs

What participation looks like

If you qualify, you will first take a genetic blood test to confirm you have the right genetic makeup for the study. Then you'll be randomly assigned to one of three groups: taking the new medication by mouth every day, taking it daily plus receiving immunotherapy infusions every three weeks, or receiving your doctor's choice of standard treatments. You will have regular medical visits and blood tests to monitor how you're responding and check for side effects, with treatment continuing for up to about two years.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Testing a new skin cancer drug alone and with immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(9 sites)